long intergenic non-protein coding RNA 691Genealiases: []
Q-omics provides the consensus-scored LINC00691 profile across patient tissues and cancer cell-line models. LINC00691 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, LINC00691 is differentially expressed in 6, with the highest sampling consensus in BLCA. Additionally, LINC00691 RNA expression shows 9,257 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, BLCA, and THYM as cancer lineages where LINC00691 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00691 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00691 survival associations across molecular data types. LINC00691 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00691 RNA expression–survival associations across cancer types. High LINC00691 expression shows unfavorable associations in KICH, KIRC, READ, LIHC and STAD, but favorable associations in HNSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for LINC00691 RNA expression.
This table summarizes LINC00691 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00691. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00691 shows lower tumor expression in THCA and KIRP and higher tumor expression in BLCA, HNSC, LIHC and LUSC. The BLCA box plot shows higher LINC00691 RNA expression in tumor versus normal tissue (log2 FC = +0.078, t-test p = .001).
This table shows molecular features associated with LINC00691 in patient tissues and cancer cell lines. In patient samples, LINC00691 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
